Abstract Number: 2562 • 2018 ACR/ARHP Annual Meeting
Secukinumab Improves Grappa-Omeract Core Domains of Psoriatic Arthritis
Background/Purpose: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has demonstrated efficacy for patients with psoriatic arthritis (PsA) in multiple phase 3 clinical…Abstract Number: 2563 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of a Potent and Highly Selective Oral Tyrosine Kinase 2 Inhibitor, BMS-986165, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Placebo-Controlled Trial
Background/Purpose: BMS-986165, a potent and highly selective oral tyrosine kinase 2 inhibitor, inhibits signal transducer and activator of transcription (STAT)-dependent signalling pathways of interleukin-23 and…Abstract Number: 2564 • 2018 ACR/ARHP Annual Meeting
Secukinumab Efficacy in Psoriatic Arthritis: Individual Patient Meta-Analysis of Four Phase 3 Trials in 2049 Patients
Background/Purpose: Secukinumab provided rapid, significant and sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) in multiple Phase 3 studies.1-4 Herein, we report…Abstract Number: 2565 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). We report the safety, tolerability, and efficacy of tofacitinib in…Abstract Number: 2566 • 2018 ACR/ARHP Annual Meeting
Impact of Guselkumab Versus Placebo and Adalimumab on Patient Reported Outcomes in Patients with and without Psoriatic Arthritis in a Phase 3 Pivotal Psoriasis Study
Background/Purpose: VOYAGE 2 is a phase 3 double-blind, placebo/active comparator-controlled trial comparing guselkumab (GUS) with placebo (PBO) and adalimumab (ADA) in patients (pts) with moderate-to-severe…Abstract Number: 2567 • 2018 ACR/ARHP Annual Meeting
Clinically Meaningful Improvement in Skin and Nail Psoriasis in Bio-Naïve Active Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Results through Week 24 from a Phase 3 Study
Background/Purpose: GO-VIBRANT was a Phase 3 trial of intravenous (IV) golimumab (GLM) in adult patients (pts) w/active psoriatic arthritis (PsA). To evaluate improvement in skin,…Abstract Number: 2568 • 2018 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial
Background/Purpose: Secukinumab (SEC), a fully human monoclonal IgG1 antibody, provided rapid and significant improvements in all key clinical domains of psoriatic arthritis (PsA) in the…Abstract Number: 2569 • 2018 ACR/ARHP Annual Meeting
Association of Enthesitis with Achievement of Normal Quality of Life and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Adalimumab
Background/Purpose: Enthesitis, a key pathology in non-radiographic axial spondyloarthritis (nr-axSpA), has been difficult to treat with conventional therapies and may take longer to resolve than…Abstract Number: 2570 • 2018 ACR/ARHP Annual Meeting
Probability of Achieving Low Disease Activity or Remission in Subjects with Active Psa Treated with Apremilast
Background/Purpose: The ability to predict responses to apremilast (APR) could impact treatment decisions. This post-hoc analysis was conducted to (1) assess the predictive values of…Abstract Number: 2571 • 2018 ACR/ARHP Annual Meeting
Adalimumab Serum Concentration Fails to Predict Achievement of Sustained Remission or Absence of Flare for Patients with Non-Radiographic Axial Spondyloarthritis
Background/Purpose: In patients (pts) with active non-radiographic axial spondyloarthritis (nr-axSpA) in the ABILITY-3 study who achieved sustained remission with adalimumab (ADA), continued ADA therapy was…Abstract Number: 2572 • 2018 ACR/ARHP Annual Meeting
Predictors for Use of Secukinumab 300mg over 150mg in Psoriatic Arthritis: A Meta-Analysis of Four Phase 3 Trials By Machine Learning
Background/Purpose: Subcutaneous secukinumab 150mg and 300mg are approved doses for the treatment of psoriatic arthritis (PsA) with the higher dose recommended for patients with anti-TNF inadequate…Abstract Number: 2573 • 2018 ACR/ARHP Annual Meeting
The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Targeting Disease Remission in Axial Spondyloarthritis: A Systematic Literature Review
Background/Purpose: The treat-to-target concept is currently recommended in Axial Spondyloarthritis (axSpA) and remission is the main objective of treatment. Although consensual definitions of remission are…Abstract Number: 2574 • 2018 ACR/ARHP Annual Meeting
Tapering TNF Inhibitors in Axial Spondyloarthritis: Systematicanalysisoftheliteratureandmeta-Analysis
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective in treating patients with axial spondyloarthritis (axSpA), but they are associated with adverse effects and high costs.…Abstract Number: 2575 • 2018 ACR/ARHP Annual Meeting
Long-Term Effects of TNF-Alpha Inhibitors on Bone Mineral Density and the Incidence of Vertebral Fractures in Patients with Ankylosing Spondylitis
Background/Purpose: Ankylosing Spondylitis (AS) is not only characterized by pathological bone formation leading to ankylosis, but also by bone loss which may lead to vertebral…Abstract Number: 2576 • 2018 ACR/ARHP Annual Meeting
Anti-Drug Antibodies, Efficacy, and Impact of Concomitant Methotrexate in Ixekizumab-Treated Patients with Psoriatic Arthritis
Background/Purpose: Anti-drug antibody (ADA) development can potentially affect the efficacy of biologics; concomitant MTX decreases the development of ADA for some biologics.1 Ixekizumab (IXE), a…
ACR Meeting Abstracts